Urolithin A mediates p38/MAPK pathway to inhibit osteoclast activity

doi:10.12307/2023.893

Abstract

Abstract: BACKGROUND: Overactive osteoclasts disrupt bone homeostasis and play a bad role in the pathological mechanisms of related skeletal diseases, such as osteoporosis, fragility fractures, and osteoarthritis. Studies have confirmed that ellagic acid and ellagtannin have the potential to inhibit osteoclast differentiation. As their natural metabolites, urolithin A has antioxidant, anti-inflammatory, anti-proliferative and anti-cancer effects, but its effect on osteoclast differentiation and its underlying molecular mechanisms remain unclear.
OBJECTIVE: To explore the effect of urolithin A on osteoclast differentiation induced by receptor activator for nuclear factor-κB ligand and its mechanism.
METHODS: Mouse mononuclear macrophage leukemia cells (RAW264.7) that grew stably were cultured in vitro. Toxicity of urolithin A (0, 0.1, 0.5, 1.5, 2.5 μmol/L) to RAW264.7 cells were detected by cytotoxic MTS assay to screen out the safe concentration. Different concentrations of urolithin A were used again to intervene with receptor activator for nuclear factor-κB ligand-induced differentiation of RAW264.7 cells in vitro. Then, tartrate-resistant acid phosphatase staining and F-actin ring and nucleus staining were performed to observe its effect on the formation and function of osteoclasts. Finally, the expressions of urolithin A on upstream and downstream genes and proteins in the MAPK signaling pathway were observed by western blot and RT-qPCR assays.
RESULTS AND CONCLUSION: Urolithin A inhibited osteoclast differentiation and F-actin ring formation in a concentration-dependent manner and 2.5 μmol/L had the strongest inhibitory effect. Urolithin A inhibited the mRNA expression of Nfatc1, Ctsk, Mmp9 and Atp6v0d2 and the protein synthesis of Nfatc1 and Ctsk, related to osteoclast formation and bone resorption. Urolithin A inhibited the activity of osteoclasts by downregulating the phosphorylation of p38 protein to inhibit the mitogen-activated protein kinase signaling pathway.

Key words: urolithin A, osteoclast, MAPK, p38, RANKL

CLC Number:

Huang Haoran, Fan Yinuo, Wei-Yang Wenxiang, Jiang Mengyu, Fang Hanjun, Wang Haibin, Chen Zhenqiu, Liu Yuhao, Zhou Chi. Urolithin A mediates p38/MAPK pathway to inhibit osteoclast activity[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(8): 1149-1154.

Figures/Tables 5

References

[1] SEEBACH E, KUBATZKY KF. Chronic Implant-Related Bone Infections-Can Immune Modulation be a Therapeutic Strategy? Front Immunol. 2019; 10:1724.
[2] WALSH MC, KIM N, KADONO Y, et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol. 2006;24:33-63.
[3] ZHAO H, LU A, HE X. Roles of MicroRNAs in Bone Destruction of Rheumatoid Arthritis. Front Cell Dev Biol. 2020;8:600867.
[4] RAUT N, WICKS SM, LAWAL TO, et al. Epigenetic regulation of bone remodeling by natural compounds. Pharmacol Res. 2019;147:104350.
[5] DEL PUENTE A, ESPOSITO A, DEL PUENTE A, et al. Physiopathology of osteoporosis: from risk factors analysis to treatment. J Biol Regul Homeost Agents. 2015;29(3):527-531.
[6] PARK DR, KIM J, KIM GM, et al. Osteoclast-associated receptor blockade prevents articular cartilage destruction via chondrocyte apoptosis regulation. Nat Commun. 2020;11(1):4343.
[7] KIM JH, KIM N. Signaling Pathways in Osteoclast Differentiation. Chonnam Med J. 2016;52(1):12-17.
[8] KIM JH, KIM N. Regulation of NFATc1 in Osteoclast Differentiation. J Bone Metab. 2014;21(4):233-241.
[9] MARTIN TJ. Historically significant events in the discovery of RANK/RANKL/OPG. World J Orthop. 2013;4(4):186-197.
[10] LIU J, ZHANG HX, LU XX, et al. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: sensitivity and trim and fill studies. Genet Test Mol Biomarkers. 2014;18(2):117-122.
[11] D’AMICO D, ANDREUX PA, VALDÉS P, et al. Impact of the Natural Compound Urolithin A on Health, Disease, and Aging. Trends Mol Med. 2021;27(7):687-699.
[12] SAHA P, YEOH BS, SINGH R, et al. Gut Microbiota Conversion of Dietary Ellagic Acid into Bioactive Phytoceutical Urolithin A Inhibits Heme Peroxidases. PLoS One. 2016;11(6):e0156811.
[13] NORDEN E, HEISS EH. Urolithin A gains in antiproliferative capacity by reducing the glycolytic potential via the p53/TIGAR axis in colon cancer cells. Carcinogenesis. 2019;40(1):93-101.
[14] LIN X, YUAN G, LI Z, et al. Ellagic acid protects ovariectomy-induced bone loss in mice by inhibiting osteoclast differentiation and bone resorption. J Cell Physiol. 2020;35(9):5951-5961.
[15] RANTLHA M, SAGAR T, KRUGER MC, et al. Ellagic acid inhibits RANKL-induced osteoclast differentiation by suppressing the p38 MAP kinase pathway. Arch Pharm Res. 2017;40(1):79-87.
[16] XU H, CHEN F, LIU T, et al. Ellagic acid blocks RANKL-RANK interaction and suppresses RANKL-induced osteoclastogenesis by inhibiting RANK signaling pathways. Chem Biol Interact. 2020;331:109235.
[17] LEE HJ, JUNG YH, CHOI GE, et al. Urolithin A suppresses high glucose-induced neuronal amyloidogenesis by modulating TGM2-dependent ER-mitochondria contacts and calcium homeostasis. Cell Death Differ. 2021;28(1):184-202.
[18] KIM KB, LEE S, KIM JH. Neuroprotective effects of urolithin A on H(2)O(2)-induced oxidative stress-mediated apoptosis in SK-N-MC cells. Nutr Res Pract. 2020;14(1):3-11.
[19] DASILVA NA, NAHAR PP, MA H, et al. Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation in vitro. Nutr Neurosci. 2019;22(3):185-195.
[20] RIGGS BL, WAHNER HW, DUNN WL, et al. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981;67(2):328-335.
[21] RIGGS BL, WAHNER HW, SEEMAN E, et al. Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest. 1982;70(4):716-723.
[22] O’BRIEN MS, MCDOUGALL JJ. Age and frailty as risk factors for the development of osteoarthritis. Mech Ageing Dev. 2019;180:21-28.
[23] PEREIRA D, SEVERO M, RAMOS E, et al. Potential role of age, sex, body mass index and pain to identify patients with knee osteoarthritis. Int J Rheum Dis. 2017;20(2):190-198.
[24] MURATOVIC D, FINDLAY DM, CICUTTINI FM, et al. Bone matrix microdamage and vascular changes characterize bone marrow lesions in the subchondral bone of knee osteoarthritis. Bone. 2018;108:193-201.
[25] XU Q, CAO Z, XU J, et al. Effects and mechanisms of natural plant active compounds for the treatment of osteoclast-mediated bone destructive diseases. J Drug Target. 2022;30(4):394-412.
[26] HUANG WC, LIOU CJ, SHEN SC, et al. Urolithin A Inactivation of TLR3/TRIF Signaling to Block the NF-κB/STAT1 Axis Reduces Inflammation and Enhances Antioxidant Defense in Poly(I:C)-Induced RAW264.7 Cells. Int J Mol Sci. 2022;23(9):4697.
[27] KOMATSU W, KISHI H, YAGASAKI K, et al. Urolithin A attenuates pro-inflammatory mediator production by suppressing PI3-K/Akt/NF-κB and JNK/AP-1 signaling pathways in lipopolysaccharide-stimulated RAW264 macrophages: Possible involvement of NADPH oxidase-derived reactive oxygen species. Eur J Pharmacol. 2018;833:411-424.
[28] ZHANG W, CHEN JH, AGUILERA-BARRANTES I, et al. Urolithin A suppresses the proliferation of endometrial cancer cells by mediating estrogen receptor-α-dependent gene expression. Mol Nutr Food Res. 2016;60(11):2387-2395.
[29] ALAUDDIN M, OKUMURA T, RAJAXAVIER J, et al. Gut Bacterial Metabolite Urolithin A Decreases Actin Polymerization and Migration in Cancer Cells. Mol Nutr Food Res. 2020;64(7):e1900390.
[30] HSU H, LACEY DL, DUNSTAN CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999; 96(7):3540-3545.
[31] HAYMAN AR. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity. 2008;41(3):218-223.
[32] VääNäNEN HK, ZHAO H, MULARI M, et al. The cell biology of osteoclast function. J Cell Sci. 2000;113(Pt 3):377-381.
[33] LIU Y, WANG Z, MA C, et al. Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity. J Cell Mol Med. 2020;24(6):3303-3313.
[34] TAKAYANAGI H, KIM S, KOGA T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell. 2002;3(6):889-901.
[35] LIU Y, WANG C, WANG G, et al. Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics. 2019;9(16):4648-4662.
[36] LOTINUN S, KIVIRANTA R, MATSUBARA T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest. 2013;123(2):666-681.
[37] WU H, XU G, LI YP. Atp6v0d2 is an essential component of the osteoclast-specific proton pump that mediates extracellular acidification in bone resorption. J Bone Miner Res. 2009;24(5):871-885.
[38] KIM Y, KIM J, LEE H, et al. Tetracycline Analogs Inhibit Osteoclast Differentiation by Suppressing MMP-9-Mediated Histone H3 Cleavage. Int J Mol Sci. 2019;20(16):4038.
[39] LEE K, SEO I, CHOI MH, et al. Roles of Mitogen-Activated Protein Kinases in Osteoclast Biology. Int J Mol Sci. 2018;19(10):3004.
[40] WEI W, PENG C, GU R, et al. Urolithin A attenuates RANKL-induced osteoclastogenesis by co-regulating the p38 MAPK and Nrf2 signaling pathway. Eur J Pharmacol. 2022;921:174865.